Desta Z - Search Results

1

Pimozide Alleviates Hyperglycemia in Diet-Induced Obesity by Inhibiting Skeletal Muscle Ketone Oxidation.

Al Batran R, Gopal K, Capozzi ME, Chahade JJ, Saleme B, Tabatabaei-Dakhili SA, Greenwell AA, Niu J, Almutairi M, Byrne NJ, Masson G, Kim R, Eaton F, Mulvihill EE, Garneau L, Masters AR, Desta Z, Velázquez-Martínez CA, Aguer C, Crawford PA, Sutendra G, Campbell JE, Dyck JRB, Ussher JR. Al Batran R, et al. Among authors: desta z. Cell Metab. 2020 May 5;31(5):909-919.e8. doi: 10.1016/j.cmet.2020.03.017. Epub 2020 Apr 9. Cell Metab. 2020. PMID: 32275862 Free article.

2

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.

Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. Ogburn ET, et al. Among authors: desta z. Drug Metab Dispos. 2010 Jul;38(7):1218-29. doi: 10.1124/dmd.109.031393. Epub 2010 Mar 24. Drug Metab Dispos. 2010. PMID: 20335270 Free PMC article.

3

Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS.

Masters AR, McCoy M, Jones DR, Desta Z. Masters AR, et al. Among authors: desta z. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Mar 15;1015-1016:201-208. doi: 10.1016/j.jchromb.2016.02.018. Epub 2016 Feb 18. J Chromatogr B Analyt Technol Biomed Life Sci. 2016. PMID: 26946423 Free PMC article.

4

Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.

Masters AR, Gufford BT, Lu JB, Metzger IF, Jones DR, Desta Z. Masters AR, et al. Among authors: desta z. J Pharmacol Exp Ther. 2016 Aug;358(2):230-8. doi: 10.1124/jpet.116.232876. Epub 2016 Jun 2. J Pharmacol Exp Ther. 2016. PMID: 27255113 Free PMC article. Clinical Trial.

5

Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers.

Gufford BT, Metzger IF, Bamfo NO, Benson EA, Masters AR, Lu JBL, Desta Z. Gufford BT, et al. Among authors: desta z. J Pharmacol Exp Ther. 2022 Jul 7;382(3):313-26. doi: 10.1124/jpet.122.001277. Online ahead of print. J Pharmacol Exp Ther. 2022. PMID: 35798386 Free PMC article.

6

In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19.

Xu C, Desta Z. Xu C, et al. Among authors: desta z. Drug Metab Pharmacokinet. 2013;28(4):362-71. doi: 10.2133/dmpk.dmpk-12-rg-124. Epub 2013 Feb 5. Drug Metab Pharmacokinet. 2013. PMID: 23385314 Free PMC article.

7

Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.

Xu C, Ogburn ET, Guo Y, Desta Z. Xu C, et al. Among authors: desta z. Drug Metab Dispos. 2012 Apr;40(4):717-25. doi: 10.1124/dmd.111.042416. Epub 2012 Jan 9. Drug Metab Dispos. 2012. PMID: 22232427 Free PMC article.

8

Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism.

Rae JM, Soukhova NV, Flockhart DA, Desta Z. Rae JM, et al. Among authors: desta z. Drug Metab Dispos. 2002 May;30(5):525-30. doi: 10.1124/dmd.30.5.525. Drug Metab Dispos. 2002. PMID: 11950782

9

Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Desta Z, Zhao X, Shin JG, Flockhart DA. Desta Z, et al. Clin Pharmacokinet. 2002;41(12):913-58. doi: 10.2165/00003088-200241120-00002. Clin Pharmacokinet. 2002. PMID: 12222994 Review.

10

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. Ward BA, et al. Among authors: desta z. J Pharmacol Exp Ther. 2003 Jul;306(1):287-300. doi: 10.1124/jpet.103.049601. Epub 2003 Apr 3. J Pharmacol Exp Ther. 2003. PMID: 12676886

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

183 results

Search Page